5-Alpha Reductase Inhibitors Use in Prostatic Disease and Beyond
March 2023
in “
Translational Andrology and Urology
”
Studysummary This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tau.amegroups.com →